ACHMEA BV

Their core work

Achmea is one of the largest insurance and healthcare groups in the Netherlands, best known for its health insurance brands including Zilveren Kruis. In H2020 research consortia, Achmea participates as an industry partner that bridges academic research and real-world healthcare delivery — bringing access to large-scale patient population data, insurance claims data, and the operational infrastructure to test findings at scale. Their EU project involvement reflects a strategic push to apply big data analytics to population health management, reducing costs and improving outcomes across their insured population. They represent the payer and healthcare systems perspective that most academic consortia lack.

What they specialise in

How they've shifted over time

Achmea's first H2020 project (ADVOCATE, 2015) addressed oral and preventive care — a relatively conventional health insurance interest with no detailed keywords captured in the data. By 2018, their focus shifted sharply toward big data infrastructure for healthcare: BigMedilytics brought explicit engagement with data analytics platforms, oncology use cases, and the industrialization of care delivery at scale. The trajectory is clear: from specific preventive-health programmes toward systemic, data-driven population health management, likely driven by internal pressure to use analytics for cost control and outcome improvement across their insured base.

Achmea is moving toward large-scale healthcare data infrastructure and analytics — organizations building EU health data consortia or clinical AI platforms should consider them as an industry anchor with real patient data and implementation reach.

How they like to work

Achmea consistently joins as a participant rather than a coordinator — they do not lead EU projects but bring industry weight and real-world data assets to research-led consortia. Their combined 45 unique partners across just two projects suggests they work within large, multi-stakeholder consortia typical of H2020 Innovation Actions. This pattern is common for large industry actors who want to shape research agendas and access outputs without carrying project management overhead.

Achmea has engaged with 45 unique consortium partners across 14 countries through only two projects, indicating participation in large, internationally diverse consortia. No dominant geographic cluster is evident beyond the standard Western European composition of H2020 health and ICT projects.

What sets them apart

Achmea's value in research consortia is rare: as a major health insurer managing millions of patients, they can offer access to real-world population-scale health data and a direct route to implementation that academic or SME partners cannot replicate. For any project needing a credible industry end-user in health data, payer systems, or preventive care, Achmea provides both legitimacy and a live testing ground. Their combination of health insurance operations and ICT investment positions them at exactly the intersection where EU health data infrastructure policy is heading.

Highlights from their portfolio

• BigMedilytics
  The largest and most keyword-rich project in Achmea's portfolio, this 2018–2021 Innovation Action placed them at the centre of EU efforts to apply big data to medical analytics, covering oncology, population health, and healthcare industrialization.
• ADVOCATE
  Achmea's first H2020 project (2015–2019) shows an early, perhaps exploratory, move into EU-funded health research through oral care — a lower-profile entry point that preceded their more strategically significant data analytics involvement.